您的位置: 首页 > 农业专利 > 详情页

Hepatitis c virus inhibitors
专利权人:
BRISTOL-MYERS SQUIBB COMPANY
发明人:
BELEMA MAKONEN,ROMINE JEFFREY LEE,NGUYEN VAN N.,WANG GAN,LOPEZ OMAR D.,ST. LAURENT DENIS R.,CHEN QI,BENDER JOHN A.,YANG ZHONG,HEWAWASAM PIYASENA,XU NINGNING,MEANWELL NICHOLAS A.,EASTER JOHN A.,SU BAO-
申请号:
NZ60122010
公开号:
NZ601220A
申请日:
2010.12.13
申请国别(地区):
NZ
年份:
2014
代理人:
摘要:
Disclosed are methyl ((1S)-1-(((2S)-2-(4-(4&rsquo-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetyl)-2-pyrrolidinyl)-4-chloro-1H-imidazol-5-yl)-4-biphenylyl)-1H-5-chloro-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate derivatives as represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is 0, 1, or 2 X is selected from hydrogen, alkenyl, cyano, cycloalkyl, (cycloalkyl)alkyl, halo, and heterocyclyl R1 is selected from hydrogen and halo R2 is selected from hydrogen, alkenyl, cyano, cycloalkyl, (cycloalkyl)alkyl, halo, and heterocyclyl or R1 and R2, together with the carbon atoms to which they are attached, form a six-membered aromatic ring optionally substituted with one halo group provided that at least one of X and R2 is selected from alkenyl, cyano, cycloalkyl, (cycloalkyl)alkyl, halo, and heterocyclyl each R3 is alkyl, wherein the alkyl can optionally form a fused three- or four-membered ring with an adjacent carbon atom or a spirocyclic three- or four-membered ring with the carbon atom to which it is attached wherein the fused and spirocyclic rings are optionally substituted with one or two alkyl groups each R4 is independently selected from hydrogen and -C(O)R5 and each R5 is independently selected from alkoxy, alkyl, arylalkoxy, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, (NRcRd)alkenyl, and (NRcRd25 )alkyl and wherein the remaining substituents are as defined herein. Further disclosed is a composition comprising a compound as defined above, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and optionally further comprising at least one additional compound having anti-HCV activity, for treating an HCV infection in a patient.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充